HealthEquity, Inc.
HealthEquity, Inc. (HQY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hqy · pe ratio · data through Jan 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for HealthEquity, Inc. (HQY) measures how much investors pay for each dollar of the company's trailing earnings. HQY's current PE ratio of 32.19x is calculated by dividing its stock price of $88.07 by its TTM earnings per share of $2.73. −84.9% discount vs 5Y avg 213.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-01-31
PE Ratio History
2013 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 12 fiscal years · Front-end computedMinQ1 · 25%76.6x
MedianQ3 · 75%704.6x
Max
At 32.19x, HQY's current P/E is lower than in 8% of its annual fiscal year readings over the past 12 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Healthcare Information Services · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
HealthEquity, Inc.You HQY | $7.4B | 32.19x | +8.0% | $2.73 |
 Bio-Rad Laboratories, Inc. BIO | $8.0B | 10.87x | -63.5% | $27.87 |
 BrightSpring Health Services, Inc. Common Stock BTSG | $11.3B | 39.79x | +33.5% | $0.94 |
 Corcept Therapeutics Incorporated CORT | $7.9B | 36.27x | +21.7% | $0.96 |
 DaVita Inc. DVA | $12.3B | 13.10x | -56.1% | $8.67 |
 Globus Medical, Inc. GMED | $10.7B | 21.94x | -26.4% | $3.98 |
 Hims & Hers Health, Inc. HIMS | $6.0B | 56.90x | +90.9% | $0.57 |
Industry Average 6 peers with valid PE | — | 29.81x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-01-31Latest FY2026 | 34.29x | $2.50 | -65.4% | |
2025-01-31 FY2025 | 99.19x | $1.11 | -14.5% | |
2024-01-31 FY2024 | 116.08x | $0.65 | — | |
2023-01-31 FY2023 | — | $-0.31 | — | |
2022-01-31 FY2022 | — | $-0.53 | — | |
2021-01-31 FY2021 | 704.62x | $0.12 | +531.2% | |
2020-01-31 FY2020 | 111.63x | $0.59 | +114.0% | |
2019-01-31 FY2019 | 52.16x | $1.20 | -19.1% | |
2018-01-31 FY2018 | 64.45x | $0.79 | -37.3% | |
2017-01-31 FY2017 | 102.78x | $0.45 | +41.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for HealthEquity, Inc. (HQY) measures how much investors pay for each dollar of the company's trailing earnings. HQY's current PE ratio of 32.19x is calculated by dividing its stock price of $88.07 by its TTM earnings per share of $2.73.
Frequently asked questions
HQY pe ratio · 6 questionsHQY's current PE ratio is 32.19x as of 2026-06-08, based on a stock price of $88.07 and TTM EPS of $2.73. Data sourced from Financial Modeling Prep via HQY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · HealthEquity, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08